ClinVar Miner

Submissions for variant NM_020975.6(RET):c.2556C>G (p.Ile852Met) (rs377767426)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000204335 SCV000261072 uncertain significance Multiple endocrine neoplasia, type 2 2018-12-28 criteria provided, single submitter clinical testing This sequence change replaces isoleucine with methionine at codon 852 of the RET protein (p.Ile852Met). The isoleucine residue is highly conserved and there is a small physicochemical difference between isoleucine and methionine. This variant is present in population databases (rs377767426, ExAC 0.04%). This variant has been observed in several individuals affected with medullary thyroid cancer and non-small cell lung cancer (PMID: 11295841, 21711375, 28578594, 26556299, 27525386). Additionally, this variant has been observed in an individual affected with multiple endocrine neoplasia type 2 (MEN2A)(PMID: 24745698) and has been reported to co-segregate with a pathogenic RET variant in a family with MEN2A (PMID: 26876062). ClinVar contains an entry for this variant (Variation ID: 24955). Experimental studies have shown that this missense change may increase RET kinase activity in vitro (PMID: 21711375). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Ambry Genetics RCV000566408 SCV000674738 uncertain significance Hereditary cancer-predisposing syndrome 2018-02-21 criteria provided, single submitter clinical testing Lines of evidence used in support of classification: Insufficient or conflicting evidence,Conflicting evidence
Counsyl RCV000662415 SCV000784850 uncertain significance Multiple endocrine neoplasia, type 2a 2017-01-16 criteria provided, single submitter clinical testing
Equipe Genetique des Anomalies du Developpement,Université de Bourgogne RCV000755693 SCV000883124 uncertain significance Multiple endocrine neoplasia, type 2b 2018-11-21 criteria provided, single submitter clinical testing
Research and Development, ARUP Laboratories RCV000021869 SCV000042535 uncertain significance not specified 2018-05-04 no assertion criteria provided literature only First report: single family, 2 have the mutation: 1 MTC at 20 yr. Second report (database submission): single individual with MTC at 65 yr. Third report: single family, five have the mutation: 1 MTC at 64 yr. Two recent reports indicate that p.I852M is likely a rare polymorphism, likely benign (PMID 28578594 and 29656518). For example, in a single Dutch family, three have the mutation: 1 MTC at 69 yr, 2 with C-cell hyperplasia at 39 and 42 yr. The MTC had a somatic RET mutation that was likely responsible for the cancer development versus the germline p.I852M mutation (PMID 28578594). Present in GnomAD at 0.017%, fairly common for uncommon disease ( In vitro studies indicate weakly activating mutation: PMID 21711375. Has been found with another RET change, see c.[1901G>A;2556C>G].

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.